Rimabotulinumtoxinb

CHEMBL1201569 Phase 4 Disetujui Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

Rimabotulinumtoxin B is a botulinum neurotoxin type B that cleaves the vesicle-associated membrane protein (VAMP/synaptobrevin) component of the SNARE complex at peripheral cholinergic nerve terminals, preventing acetylcholine release and causing localized, temporary muscle paralysis or glandular secretion reduction. It is approved for the treatment of cervical dystonia and hyperhidrosis, and is used off-label for spasticity in multiple sclerosis and post-stroke conditions.

Area Terapeutik

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

Rimabotulinumtoxin B is a botulinum neurotoxin type B that cleaves the vesicle-associated membrane protein (VAMP/synaptobrevin) component of the SNARE complex at peripheral cholinergic nerve terminals, preventing acetylcholine release and causing localized, temporary muscle paralysis or glandular secretion reduction. It is approved for the treatment of cervical dystonia and hyperhidrosis, and is used off-label for spasticity in multiple sclerosis and post-stroke conditions.

Yes, Rimabotulinumtoxinb is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201569. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.